News

The study successfully demonstrated the tolerability of the two concentrations tested for continuous application to the skin for a period of one week. Additionally, there was no systemic

Xoma, a biopharmaceutical company, and Takeda Pharmaceutical Company have expanded their existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of R&D technologies

The reduction in costs is targeted at Akela’s development programs, as well as its service business, PharmaForm. Akela has initiated the Phase III clinical trials in its lead

The new contract is expected to generate $5 million in sales for Medline, while CHS is in line to realize a 20% supply cost savings through formulary standardization,

ATryn is said to be the first ever transgenically produced therapeutic protein and the first recombinant antithrombin approved in the US. It is now also the first recombinant

If approved, Arzerra (ofatumumab) would be indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have previously failed, or are inappropriate for, standard therapies. Ofatumumab

In his most recent endeavor, he served as chief executive officer (CEO) of Living Cell Technologies. He was earlier president and CEO of Aurogen, a privately held biotech

For the fourth quarter period, revenues were $20.8 million, against $19.7 million from the prior-year period. The company recorded operating income of $1.1 million for the three-month period,

GAAP net income rose to $86.7 million, or $0.31 per diluted share, compared with $78.9 million, or $0.29 per diluted share, in the prior fourth quarter. Non-GAAP net